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This letter reports a chemiluminescene immunoassay method combined with immunomagnetic separation to rapidly detect Cyfra 
21-1, in which bio-functionlized magnetic nanocomposites were used as mobile substrate for capturing and isolating the cyfra 
21-1 proteins. After the captured Cyfra 21-1 further reacted with horseradish peroxidase-conjugated anti-Cyfra 21-1 antibody to 
form a sandwich immunocomplex, the chemiluminescence would be produced as a result of addition of the chemiluminescent 
substrate. A home-made optical biosensor was designed to detect the chemiluminescence instead of other large instruments. There 
is a good linear response between the chemiluminescence intensity and the concentration of Cyfra 21-1 in the range from 0.2 to 50 
ng/mL. The whole detection process including incubation, washing and detection could be performed within 45 min. The pro-
posed method offers a simple, noninvasive and reliable tool for detecting non-small cell lung cancer and has potential application 
for clinical testing. 
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Lung cancer is among the most common and lethal cancers 
worldwide. There were an estimated 1.61 million new cases 
with 1.38 million deaths in 2008 [1]. Non-small cell lung 
cancer (NSCLC) is one broad histological type of lung can-
cer and comprises approximately 85% of lung cancer cases. 
Tumor markers have been a complementary test in provid-
ing both an indication of response to therapy and disease 
progression or recurrence in cancer patients. Numerous tu-
mor markers have been studied for potential use in NSCLC, 
such as carcinoembryonic antigen, squamous cell carcinoma, 
cytokeratin fragment 21-1 (Cyfra 21-1) and so on [2,3]. Of 
these, Cyfra 21-1 has been reported to be the most sensitive 
marker for NSCLC, and has considerable potential for early 
diagnostic of NSCLC, monitoring treatment response of 
patients and detecting recurrent disease after primary therapy.  
The Cyfra 21-1 assay is a quantitative measurement of 
cytokeratin 19 fragments. The cytokeratins are a subfamily 
of intermediate filament-forming proteins containing at least 
20 different polypeptides found in the intracytoplasmic cy-
toskeleton of epithelial tissue [4]. Cytokeratin 19 is espe-
cially expressed in simple epithelial cells and considered 
one of the main tumor markers for detection of NSCLC in 
the clinic. Up to date, several methods have been proposed 
to detect the Cyfra 21-1 concentration in body fluids, in-
cluding radioimmunoassay [3,5], electrochemiluminsecent 
immunoassay [6], enzyme-linked immunosorbent assay 
[7,8], and chemiluminescent immunoassay (CLIA) [9,10]. 
The CLIA has gained increasing attentions due to the ex-
cellent properties, such as having high sensitivity, good 
specificity, simple equipment and wide linear range. How-
ever, limitations in the traditional CLIA method still remain 
because antibodies are usually immobilized on a solid sub-
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strate in air which will cause several problems. For example, 
the exposure of proteins to air seriously reduces their bio-
logical activity.  
To resolve these problems, use of nanomaterials and 
nanotechnology has provided great opportunity for improv-
ing the traditional CLIA method. Here, we present our re-
cent efforts to establish a CLIA method combined with 
immunomagnetic separation to detect Cyfra 21-1, in which 
bio-functionlized magnetic nanocomposites (BFMNs) were 
used as mobile substrate for capturing and isolating the 
Cyfra 21-1 proteins. When the captured Cyfra 21-1 further 
reacted with horseradish peroxidase (HRP)-conjugated an-
ti-Cyfra 21-1 antibody to form a sandwich immunocomplex, 
the chemiluminescence would produced as a result of addi-
tion of the chemiluminescent (CL) substrate and detected by 
a home-made portable biosensor.  
The BFMNs were fabricated in advance by anchoring the 
biotin-conjugated monoclonal anti-Cyfra 21-1 antibody 
onto streptavidin-coated superparamagnetic beads through a 
streptavidin-biotin bridge. The human Cyfra 21-1 antigen 
standard grade, HRP-conjugated murine monoclonal anti-
body and biotin-conjugated murine monoclonal antibody to 
Cyfra 21-1 used in the experiment were purchased from 
Xema-Medica, and the streptavidin-coated superparamag-
netic beads M-280 with the size of the iron oxide less than 
20 nm [11] were from Dynal Biotech. To our knowledge, 
the protein concentration could be qualified by the UV 
spectrophotometry. Since no other protein was introduced 
during the antibody-beads coupling process, the anti-Cyfra 
21-1 antibody concentration could be calculated using the 
Lamber-Beer law and is proportional to the absorbency at 
280 nm wavelength. Accordingly, the ratio of the immobi-
lization antibodies in the fabrication of BFMNs was inves-
tigated by evaluated by measuring the absorbance of the 
initial antibody solution and the supernatant at 280 nm us-
ing a UV-1700 spectrophotometer (Shimadzu, Japan). The 
immobilization rate R can be obtained as 
 R = [(A0 − A1)/A0] ×100%,   (1) 
where A0 is the absorbency of the anti-Cyfra 21-1 antibody 
solution before immobilization, and A1 is that of the unfixed 
anti-Cyfra 21-1 antibody in the supernatant after immobili-
zation, respectively. It was calculated that the average im-
mobility rate of capture antibody was about 92%, indicating 
that the anti-Cyfra 21-1 capture antibody was effectively 
immobilized on the surface of superparamagnetic beads.  
The home-made optical biosensor was designed to detect 
the chemiluminescence instead of other large instrument. It 
consists of two parts: a sensitive cell and an optical detector 
module. The sensitive cell was the key part to convert the 
concentration of Cyfra 21-1 to measuerable optical signals 
on the basis of the chemiluminescence immunoassay. The 
optical detector module was fabricated according to Wang 
et al. work [12], in which a photomultiplier tube with mode 
of H57155-20 and Field Programmable Gate Array were 
used to sensitively count the emitted photons. When the 
Cyfra 21-1 captured by the BFMNs and HRP-conjugated 
antibody reacts with CL substrate to produce chemilumi-
nescence on the sensitive cell, the optical signals would be 
detected.  
Cyfra 21-1 was detected by a sandwich-type immunoas-
say using two kinds of monoclonal antibodies which could 
recognize different epitopes of Cyfra 21-1. The schematic 
diagram of the analysis protocol is shown in Figure 1. There 
are two incubation steps and one wash step. The two incu-
bation times are both no more than 15 min. Figure 2 shows 
the kinetics characteristics of CL reaction by detecting var-
ious concentrations of Cyfra 21-1 antigen standard. The CL 
reaction occurred immediately after addition of the substrate 
into the formed sandwich immunocomplex, and its intensity 
increased continuously. When the concentration of Cyfra 
21-1 is higher (50 ng/mL), the CL intensity increases rapid-
ly in the former 4 min and tends to keep stable at latter time. 
When the concentration of Cyfra 21-1 is lower, it needs 
more time for CL intensity increasing to reach a plateau. 
Since too long triggering time for CL reaction was obvi-
ously disadvantageous to the improvement of assay speed, 
the optimal CL reaction time was chosen to be 6 min. 
Therefore, the whole assay including incubation, washing 
and detection could be performed within 45 min. 
The relationship between Cyfra 21-1 concentrations and  
 
 
Figure 1  Schematic diagram of the analysis protocol.  
 
Figure 2  Kinetics curve for decreasing concentration of Cyfra 21-1 anti-
gen (50, 30, 5, 0.2 ng/mL).  
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CL intensity was investigated by the home-made biosensor. 
As shown in Figure 3, there is a good linear response be-
tween the CL intensity and the concentration of Cyfra 21-1 
in the concentration range from 0.2 to 50 ng/mL. The linear 
regression equation for Cyfra 21-1 is 
 I = 0.218C + 0.549 (R2 = 0.939),  (2) 
where I is the CL intensity and C is the concentration of 
Cyfra 21-1. The detection limit of Cyfra 21-1 was 0.2 
ng/mL (S/N≥3).  
In conclusion, this brief report provides a CLIA method 
combined with immunomagnetic separation to rapidly de-
tect Cyfra 21-1, in which BFMNs were used as mobile sub-
strate for capturing the Cyfra 21-1 proteins and the home- 
made optical biosensor was designed to detect the chemilu-
minescence instead of other large instrument. The whole 
 
 
Figure 3  Calibration curve of CL intensity versus Cyfra 21-1 at the con-
centrations ranging from 0.2 to 50 ng/mL. Each error bar was obtained 
from three measurements.  
detection process including incubation, washing, detection 
could be performed within 45 min. The characteristics of 
detecting Cyfra 21-1 were primarily investigated to validate 
the proposed method. Our further work is to improve the 
detection precision and apply the proposed method for de-
tecting clinical samples.  
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